GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipher Pharmaceuticals Inc (STU:PHE) » Definitions » EV-to-EBIT

Cipher Pharmaceuticals (STU:PHE) EV-to-EBIT : 31.10 (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cipher Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cipher Pharmaceuticals's Enterprise Value is €274.51 Mil. Cipher Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €8.83 Mil. Therefore, Cipher Pharmaceuticals's EV-to-EBIT for today is 31.10.

The historical rank and industry rank for Cipher Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

STU:PHE' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.22   Med: 5.96   Max: 72.76
Current: 31.31

During the past 13 years, the highest EV-to-EBIT of Cipher Pharmaceuticals was 72.76. The lowest was 1.22. And the median was 5.96.

STU:PHE's EV-to-EBIT is ranked worse than
73.11% of 673 companies
in the Drug Manufacturers industry
Industry Median: 17.04 vs STU:PHE: 31.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cipher Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 was €280.19 Mil. Cipher Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €8.83 Mil. Cipher Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.15%.


Cipher Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Cipher Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cipher Pharmaceuticals EV-to-EBIT Chart

Cipher Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.09 1.79 1.21 3.84 5.94

Cipher Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.61 5.94 10.99 9.07 33.17

Competitive Comparison of Cipher Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipher Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cipher Pharmaceuticals's EV-to-EBIT falls into.



Cipher Pharmaceuticals EV-to-EBIT Calculation

Cipher Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=274.506/8.827
=31.10

Cipher Pharmaceuticals's current Enterprise Value is €274.51 Mil.
Cipher Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cipher Pharmaceuticals  (STU:PHE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cipher Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=8.827/280.19062
=3.15 %

Cipher Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 was €280.19 Mil.
Cipher Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cipher Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cipher Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cipher Pharmaceuticals Business Description

Traded in Other Exchanges
Address
5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.

Cipher Pharmaceuticals Headlines

No Headlines